Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR Files for Growject Liquid Formulation
August 3, 2015
- Ono Files Opdivo for Use in Chemotherapy-Naïve Patients
August 3, 2015
- Post-Marketing Study Shows No Causal Relationship of Actos with Bladder Cancer: Takeda
August 3, 2015
- Novartis Files NDA for Acromegaly Treatment Pasireotide in Japan
August 3, 2015
- Bayer Yakuhin Files Nexavar to Expand Indication for Thyroid Cancer
August 3, 2015
- Otsuka Holdings Increases Forecasts for 1st Half of FY2015
August 3, 2015
- Wholesalers Must Ponder Use of Reps for New Business: Mediceo CEO
July 31, 2015
- Nichi-Iko to Tie Up with Thai Drug Maker to Strengthen Lineup, Accelerate Brand Penetration
July 31, 2015
- Nippon Kayaku Initiates PIII Study of Herceptin Biosimilar in Japan
July 31, 2015
- Sumitomo Dainippon’s Leigh Syndrome Drug Showed No Statistical Difference in PIIb Study in US
July 31, 2015
- Cresemba Fails to Meet Primary Endpoint in PIII Study for Candidemia: Astellas
July 31, 2015
- Eisai Files Halaven for Soft Tissue Sarcoma Simultaneously in Japan, US, Europe
July 31, 2015
- Kyowa Kirin Files NDA for Brodalumab for Psoriasis in Japan
July 31, 2015
- Kyowa Kirin, BMS to Collaborate in Study of Combination Poteligeo, Opdivo in US
July 31, 2015
- AbbVie Pres. Says Japan Attracting Foreign Investments, Confident in Hep C Drug
July 31, 2015
- Delving into Securities Filings - 3: Sales Rep Ratio at Drug Makers Up Slightly in FY2014
July 31, 2015
- Series: Delving into Securities Filings
July 31, 2015
- ASCO Immunotherapy Roundup - 4: Merck KGaA Trailing Rivals with ADCC-Inducing Avelumab
July 30, 2015
- Takecab Maintains Top Position for 6th Month Running in HP Market in June: Anterio Ranking
July 30, 2015
- Lenvima Receives Breakthrough Therapy Designation from US FDA
July 30, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…